STOCKHOLM, Sweden--(BUSINESS WIRE)--June 30, 2006--Medivir AB (STO:MVIRB) announced today the signing of two new pharmaceutical license agreements and an extension of the ongoing research collaboration in hepatitis C (HCV) with Tibotec Pharmaceuticals Ltd. In the first agreement, Medivir has outlicensed its preclinical human immunodeficiency virus (HIV) protease inhibitor project and in the second agreement provided a license for the MIV-210 polymerase inhibitor compound for HIV and hepatitis B (HBV).
